{
    "version": "1.0",
    "last_updated": "2025-01-15",
    "source": "Clinical pharmacology references",
    "interactions": [
        {
            "drug_a": "warfarin",
            "drug_b": "aspirin",
            "severity": "major",
            "mechanism": "Both affect hemostasis through different mechanisms; aspirin inhibits platelet aggregation while warfarin inhibits clotting factors",
            "clinical_effect": "Significantly increased risk of bleeding, including potentially fatal hemorrhage",
            "management": "Avoid combination if possible. If both required, use lowest aspirin dose (81mg) and monitor INR closely",
            "evidence_level": "high"
        },
        {
            "drug_a": "warfarin",
            "drug_b": "ibuprofen",
            "severity": "major",
            "mechanism": "NSAIDs inhibit platelet function and may displace warfarin from protein binding sites",
            "clinical_effect": "Increased bleeding risk and potential for serious GI hemorrhage",
            "management": "Avoid NSAIDs with warfarin. Use acetaminophen for pain if needed",
            "evidence_level": "high"
        },
        {
            "drug_a": "warfarin",
            "drug_b": "naproxen",
            "severity": "major",
            "mechanism": "NSAIDs inhibit platelet function and may displace warfarin from protein binding",
            "clinical_effect": "Increased bleeding risk and potential for serious GI hemorrhage",
            "management": "Avoid combination. Consider acetaminophen or topical analgesics",
            "evidence_level": "high"
        },
        {
            "drug_a": "lisinopril",
            "drug_b": "potassium",
            "severity": "moderate",
            "mechanism": "ACE inhibitors reduce aldosterone secretion, decreasing potassium excretion",
            "clinical_effect": "Risk of hyperkalemia with cardiac arrhythmia potential",
            "management": "Monitor potassium levels regularly; avoid potassium supplements unless hypokalemic",
            "evidence_level": "high"
        },
        {
            "drug_a": "lisinopril",
            "drug_b": "spironolactone",
            "severity": "moderate",
            "mechanism": "Both drugs can increase potassium levels through different mechanisms",
            "clinical_effect": "Significant risk of hyperkalemia",
            "management": "Monitor potassium closely if combination necessary; consider dose adjustments",
            "evidence_level": "high"
        },
        {
            "drug_a": "metformin",
            "drug_b": "alcohol",
            "severity": "moderate",
            "mechanism": "Both can contribute to lactic acidosis; alcohol impairs gluconeogenesis",
            "clinical_effect": "Increased risk of lactic acidosis and hypoglycemia",
            "management": "Limit alcohol consumption; avoid binge drinking",
            "evidence_level": "moderate"
        },
        {
            "drug_a": "atorvastatin",
            "drug_b": "gemfibrozil",
            "severity": "major",
            "mechanism": "Gemfibrozil inhibits glucuronidation and OATP1B1 transport of statins",
            "clinical_effect": "Significantly increased risk of myopathy and rhabdomyolysis",
            "management": "Avoid combination. If fibrate needed, use fenofibrate instead",
            "evidence_level": "high"
        },
        {
            "drug_a": "atorvastatin",
            "drug_b": "clarithromycin",
            "severity": "major",
            "mechanism": "Clarithromycin is a strong CYP3A4 inhibitor, increasing statin levels",
            "clinical_effect": "Increased risk of myopathy and rhabdomyolysis",
            "management": "Use azithromycin instead; if clarithromycin necessary, hold or reduce statin dose",
            "evidence_level": "high"
        },
        {
            "drug_a": "omeprazole",
            "drug_b": "clopidogrel",
            "severity": "major",
            "mechanism": "Omeprazole inhibits CYP2C19, reducing conversion of clopidogrel to active metabolite",
            "clinical_effect": "Reduced antiplatelet effect with increased cardiovascular event risk",
            "management": "Use pantoprazole or H2 blocker instead of omeprazole",
            "evidence_level": "high"
        },
        {
            "drug_a": "amoxicillin",
            "drug_b": "methotrexate",
            "severity": "moderate",
            "mechanism": "Decreased renal clearance of methotrexate by penicillins",
            "clinical_effect": "Increased methotrexate toxicity risk",
            "management": "Monitor for methotrexate toxicity; consider alternative antibiotic",
            "evidence_level": "moderate"
        },
        {
            "drug_a": "fluoxetine",
            "drug_b": "tramadol",
            "severity": "major",
            "mechanism": "Both increase serotonin levels; fluoxetine inhibits tramadol metabolism",
            "clinical_effect": "Risk of serotonin syndrome and seizures",
            "management": "Avoid combination if possible; use alternative analgesic",
            "evidence_level": "high"
        },
        {
            "drug_a": "ciprofloxacin",
            "drug_b": "theophylline",
            "severity": "major",
            "mechanism": "Ciprofloxacin inhibits CYP1A2 metabolism of theophylline",
            "clinical_effect": "Increased theophylline levels with seizure and arrhythmia risk",
            "management": "Monitor theophylline levels; reduce dose by 30-50% or use alternative antibiotic",
            "evidence_level": "high"
        }
    ]
}